Dicerna Pharmaceuticals, Inc.
Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Abstract:

Disclosed herein are methods for the treatment of cancer, comprising administering to a subject a .beta.-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of a .beta.-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.